GMP LENTIVIRUS SPECIALIZED CDMO
VIVEbiotech´s introduction
Prior experience
Key Milestones Since VIVEbiotech was created, the following milestones have been reached: •
GMP certification has been obtained
•
Sealed as Excellence Centre
•
Customers in USA and Europe
•
FDA adaptation
•
Double-manufacturing capacity
•
Commercial manufacturing capacities
CDMO
CDMO Specialized in the manufacture of Research, Preclinical toxicology and GMP-grade lentiviral vectors.
CDMO: related services
Lentisoma
Lentisoma Non-Integrative Lentiviral episomal vector
Safety-related aspects
Engineered with genetic elements from human cells that: o Govern the cellular process of genome division o Equally segregation of chromosomes in daughter cells upon cell division.
These elements are: o Ori that marks the vector to be recognised and duplicated by the cell o Scaffold/matrix attachment region (SMAR) a DNA sequence which anchors the vector genome (containing the therapeutic gene) to the nuclear matrix, avoiding its integration within the cell genome.
Lentisoma The vector genome to persist through cell divisions and concomitantly maintain a stable expression of the transgene, without integrating into the cells genome. o VIVEbiotech has secured exclusive rights to proprietary IP: ▪ Priority date 27th November 2013 ▪ National phases May 2016: Europe; USA; Israel; Canada; Japan; China and Australia
Our facilities Potenciales clientes renombrados en el mercado VIVEbiotech´s building: • Lab • Offices
Our facilities Potenciales clientes renombrados en el mercado R&D Lab
Our facilities Potenciales clientes renombrados en el mercado GMP area: USP
Our facilities Potenciales clientes renombrados en el mercado GMP area: DSP
Our team
o 40% PhDs o Multidisciplinar o Low turn-over rate o Continued increase in employees number
GMP LENTIVIRUS SPECIALIZED CDMO
